Xiaowei Zhang

Xiaowei Zhang

Auto-generated profile, based on publicly available information

Xiaowei Zhang

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
Lingjuan ZhangLingjuan Zhang
Lingjuan Zhang
CGChristian F. Guerrero-Juarez
Christian F. Guerrero-Juarez
SCStella Chen
Stella Chen
XZXiaowei Zhang
Xiaowei Zhang
MYMeimei Yin
Meimei Yin
RGRichard L. Gallo
Richard L. Gallo
Mature adipocytes that accumulate during obesity inhibit host defense against infection by feedback suppression of dermal adipocyte progenitors.

16 November 2023 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
XCXiaohui Chen
Xiaohui Chen
MGMeichun Gao
Meichun Gao
YXYongzhen Xia
Yongzhen Xia
XWXin Wang
Xin Wang
JQJingbo Qin
Jingbo Qin
XZXiao-Kun Zhang
Xiao-Kun Zhang
The orphan nuclear receptor Nur77 is a critical regulator of the survival and death of tumor cells. The pro-death effect of Nur77 can be regulated by its interaction with Bcl-2, resulting in conversion of Bcl-2 from a survival to killer. As Bcl-2 is overexpressed in various cancers preventing them from apoptosis and promoting their resistance to chemotherapy, targeting the apoptotic pathway of Nur77/Bcl-2 may lead to new cancer therapeutics. Here, we report our identification of XS561 as a novel Nur77 ligand that induces apoptosis of tumor cells by activating the Nur77/Bcl-2 pathway. In vitro and animal studies revealed an apoptotic effect of XS561 in a range of tumor cell lines including MDA-MB-231 triple-negative breast cancer (TNBC) and MCF-7/LCC2 tamoxifen-resistant breast cancer (TAMR) in a Nur77-dependent manner. Mechanistic studies showed XS561 potently induced the translocation of Nur77 from the nucleus to mitochondria, resulting in mitochondria-related apoptosis. Interestingly, XS561-induced accumulation of Nur77 at mitochondria was associated with XS561 induction of Nur77 phase separation and the formation of Nur77/Bcl-2 condensates. Together, our studies identify XS561 as a new activator of the Nur77/Bcl-2 apoptotic pathway and reveal a role of phase separation in mediating the apoptotic effect of Nur77 at mitochondria.

1 October 2021 in Immunity
Verified
Journal Article
Closed access
SLShan-Shan Liu
Shan-Shan Liu
CLChang - Liu
Chang - Liu
XLXiao-Xi Lv
Xiao-Xi Lv
BCBing Cui
Bing Cui
JYJun Yan
Jun Yan
ZHZhuowei Hu
Zhuowei Hu

13 January 2025 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
YHYechenxing He
Yechenxing He
WLWei Li
Wei Li
XZXiaowei Zhang
Xiaowei Zhang
ZCZQ Cui
ZQ Cui

29 July 2024 in Cell Proliferation
Verified
Journal Article
Open access
MYMeimei Yin
Meimei Yin
LSLixiang Sun
Lixiang Sun
SWShuai Wu
Shuai Wu
JMJinhang Ma
Jinhang Ma
WZWenlu Zhang
Wenlu Zhang
Lingjuan ZhangLingjuan Zhang
Lingjuan Zhang
Aberrant activation of dermal fibroblasts during wound healing often leads to debilitating fibrotic changes in the skin, such as scleroderma and keloids. However, the underlying cellular and molecular mechanisms remain elusive. Here, we established a wound‐induced skin fibrosis (WISF) mouse model in mature adult mice, characterised by excessive deposition of collagen bundles, loss of dermal adipocytes, and enrichment of DPP4+Ly6A+THY1+ hypodermal interstitial adipocyte progenitors (HI‐APs) and pericytes, resembling human fibrotic skin diseases. This WISF model exhibited an age‐dependent gain of fibrotic characteristics, contrasting with the wound‐induced hair neogenesis observed in younger mice. Through comprehensive analyses of the WISF, we delineated a trajectory of fibroblast differentiation that originates from HI‐APs. These progenitors highly expressed several extracellular matrix (ECM) genes and exhibited a TGFβ pathway signature. TGFβ was identified as the key signal to inhibit the adipogenic potential and maintain the fibrogenic potential of dermal APs. Additionally, administering a TGFβ receptor inhibitor to wound scar reduced the abundance of ECM‐producing APs. Finally, analysis of human scleroderma skin tissues revealed a negative correlation between the expression of AP‐, ECM‐, and TGFβ pathway‐related genes and PPARG. Overall, this study establishes a wound‐induced skin fibrosis mouse model and demonstrates that TGFβ‐mediated blockage of HI‐AP differentiation is crucial for driving fibrotic pathology. Targeting HI‐APs and adipogenesis may provide novel avenues for developing disease‐modifying therapies for fibrotic skin diseases.

20 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
WGWeijian Guo
Weijian Guo
XZXiaodong Zhu
Xiaodong Zhu
MHMingzhu Huang
Mingzhu Huang
YWYusheng Wang
Yusheng Wang
ZCZhiyu Chen
Zhiyu Chen
XWXiaoFeng Wang
XiaoFeng Wang
4014 Background: At present, there is no standard chemotherapy regimen for advanced gastric cancer (AGC), and there is no consensus whether the three-drug combination is better than two-drug combination in first-line treatment. Both of XELOX regimen and EOX regimen are widely recommended as firs-line chemotherapy regimens for AGC. In this EXELOX trial, we aimed to compare the efficacy and safety of EOX and XELOX regimens. Methods: EXELOX is an open-label, multicenter, prospective, randomized phase III trial that enrolled 448 previously untreated patients with histologically confirmed advanced gastric adenocarcinoma from 7 hospitals in China. Patients were randomly assigned (1:1) to receive XELOX regimen (oxaliplatin 130mg/m2 d1; xeloda 1000mg/m2 bid d1-14) or EOX regimen (epirubicin 50mg/m2 d1; oxaliplatin 130mg/m2 d1; xeloda 1000mg/m2 bid d1-14) in this study. Treatment was repeated every 3 weeks until disease progression, intolerable toxicity, patient death, withdrawal of informed consent, or up to eight cycles, followed by xeloda single-agent maintenance. We stratified randomization by Eastern Cooperative Oncology Group status, extent of disease(locally advanced/metastatic) and clinical trial center. Patients and clinicians were not masked to the allocated treatment. The primary endpoint was progression-free survival (PFS) on an intention-to-treat basis with a non-inferiority upper margin of 1.3 for the hazard ratio (HR). The clinical trial was a non-inferiority study that was registered with ClinicalTrials.gov, Number NCT02395640. The study is ongoing, but no longer recruit new participants. Results: Between Apr 10,2015 and Aug 20,2020, a total of 448 AGC patients were randomized to receive XELOX (n = 222) or EOX (n = 226). In ITT basis, the median PFS was 5.0 months (95%CI 4.5-6.0) in XELOX group and 5.5 months (95%CI 5.0-6.0) in EOX group (HR 0.989, 95%CI 0.812-1.203; Pnon-inferiority= 0.0032). In Per-protocol population (n = 428), the median PFS was 5.0 months (95%CI 5.0-6.0) in XELOX group and 5.5 months (95%CI 5.0-6.0) in EOX group (HR 0.983, 95%CI 0.807-1.198; Pnon-inferiority= 0.0028). The incidence of grade 3-4 adverse events (AEs) was 42.2% (90/213) in XELOX group and 72.5(156/215) in EOX group (p= 0.001). The most common grade 3-4 AEs were neutropenia (affecting 13.1% (28/213) in XELOX group and 48.4%(104/215) in EOX group (p= 0.000). The incidence of chemotherapy dose reduction was 35% (75/213) in XELOX group and 55% (120/215) in EOX group(p= 0.009). One treatment-related death (lung infection) was observed in EOX group, and none in XELOX group. Conclusions: XELOX regimen is noninferior to EOX regimen in PFS with a better safety profile as first-line treatment for AGC patients, therefore XELOX is a more favorable choice and might be one of the standard first-line chemotherapy regimens. Clinical trial information: NCT02395640.